One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States
- 1 September 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Quality and Outcomes
- Vol. 1 (1), 38-45
- https://doi.org/10.1161/circoutcomes.108.775247
Abstract
Background— Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results— The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline ( P Conclusions— These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.Keywords
This publication has 11 references indexed in Scilit:
- European PerspectivesCirculation, 2008
- One-Year Cardiovascular Event Rates in Outpatients With AtherothrombosisJAMA, 2007
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study designAmerican Heart Journal, 2006
- Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevationAmerican Heart Journal, 2006
- International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With AtherothrombosisJama-Journal Of The American Medical Association, 2006
- Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevationJournal of the American College of Cardiology, 2005
- Prevalence of and Risk Factors for Peripheral Arterial Disease in the United StatesCirculation, 2004
- Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non–ST-Segment Elevation Myocardial InfarctionJama-Journal Of The American Medical Association, 2002
- Trends in the Incidence of Myocardial Infarction and in Mortality Due to Coronary Heart Disease, 1987 to 1994New England Journal of Medicine, 1998